News | February 04, 2016

Sleep Apnea Treatment Associated with Reduced Heart Failure Readmissions

Early diagnosis with patient treatment compliance found to reduce six-month readmission rates

sleep apnea, heart failure readmissions, Thomas Jefferson University study

February 4, 2016 — Early diagnosis and treatment of sleep apnea may reduce six-month readmissions for patients hospitalized with heart failure, according to research recently published online by the American Journal of Cardiology.

“Our research showed that early recognition and treatment of patients hospitalized with decompensated congestive heart failure is associated with a reduction in readmissions, for patients who use their positive airway pressure (PAP) therapy on a regular basis,” said first author Sunil Sharma, M.D., FAASM, associate professor of pulmonary medicine in the Sidney Kimmel Medical College at Thomas Jefferson University. “Importantly, hospitals can implement cost-effective screening programs to catch sleep apnea in hospitalized, high-risk patients.”

Sharma and the team screened patients admitted to the hospital with heart failure, for underlying sleep disordered breathing. Of the 75 patients that followed up with an outpatient polysomnography, the gold standard test, 70 received the diagnosis of sleep disordered breathing. Over the next six months, the team tracked patients’ PAP compliance, emergency room visits and readmissions. Compliance was monitored objectively by the device computer and defined as a minimum of four hours of use, 70 percent of the time, for four weeks consecutively or more during the first three months of therapy.

By comparing pre- and post-treatment readmissions in compliant (n=37) and non-compliant patients (n=33), the researchers found a reduction in hospital visits for those who used their PAP regularly over a period of six months.

“Physicians should be on the lookout for sleep apnea in patients with heart failure with the goal of diagnosing and treating early, which might help prevent readmissions and emergency room visits,” Sharma said. “Multi-center, randomized studies are needed to replicate and validate these findings.”

For more information: www.ajconline.org


Related Content

News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
Subscribe Now